Accelerated Clinical Evaluation of a Monovalent Vectored Ebola vaccine

A team of UK and West African researchers is racing to test an experimental Ebola vaccine in 140 volunteers by November 2014. The vaccine targets the Zaire strain of Ebola and has already shown strong promise in pre-clinical studies at the US National Institutes of Health, developed in collaboration with Okairos (now GSK). This matters because the 2014 West African Ebola outbreak is spiralling out of control, and no licensed vaccine or treatment exists for the virus. Health care workers on the front lines face the highest risk of infection, with no medical protection beyond gloves and masks. If the vaccine proves safe and triggers a protective immune response in these 140 adults, the World Health Organization could authorise its emergency use in affected countries. The most immediate impact would be protecting health care workers, who are essential for containing the outbreak and caring for the sick. A successful vaccine could break the chain of transmission by shielding the very people who keep the response running. This is not fundamental science—it is an accelerated, real-world evaluation with a concrete deadline and a clear humanitarian goal.